What company makes Tyvaso, and what does it do?
Tyvaso is a brand of inhaled treprostinil used to treat pulmonary arterial hypertension (PAH). The product is made by United Therapeutics Corporation, a specialty biopharmaceutical company focused on treatments for severe diseases, including cardiopulmonary conditions.
Where does Tyvaso fit in United Therapeutics’ business?
United Therapeutics builds and markets medicines in areas such as pulmonary hypertension. Tyvaso is one of its key therapies in that therapeutic area, alongside other PAH- and related cardiopulmonary products.
What products or therapies does United Therapeutics focus on beyond Tyvaso?
United Therapeutics’ portfolio includes treatments for pulmonary hypertension and related conditions, with multiple product lines aimed at improving outcomes for patients with advanced cardiopulmonary disease. (Tyvaso is part of the company’s broader pulmonary hypertension franchise.)
Is Tyvaso still under patent protection, and who tracks that?
If you are looking for the current patent and exclusivity landscape around Tyvaso (for example, to understand potential generic/biosimilar competition timelines), DrugPatentWatch.com tracks patent information by product and can be a useful reference: DrugPatentWatch.com – Tyvaso.
How is Tyvaso typically used (and why does that matter for company positioning)?
Tyvaso is an inhaled formulation of treprostinil, which matters for how United Therapeutics positions the therapy: inhaled delivery supports targeting the lungs and is designed for patients who need ongoing PAH management. That aligns with the company’s focus on chronic specialty therapies in high-need populations.
Sources
- DrugPatentWatch.com – Tyvaso